# Valion Bio (VBIO) — Earnings

VBIO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vbio/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2024 |
| Period end | Sep 30, 2024 |
| EPS actual | −$97.75 |
| EPS estimate | −$2,550.00 |
| EPS surprise | +96.17% |
| Revenue surprise | −90.00% |
| Revenue | $126,000.00 |
| Revenue estimate | $1.3M |
| Reported | Nov 14, 2024 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1787740/000095017024127072/tivc-20240930.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/8b6bde83-8243-42a8-b3ff-ba9ebba3b7cd.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2024 | Nov 14, 2024 | −$2,550.00 | −$97.75 | 96.17% | $1.3M | $126,000.00 |
| Q2 2024 | Aug 14, 2024 | −$2,550.00 | −$136.00 | 94.67% | $1.1M | $140,000.00 |
| Q1 2024 | May 15, 2024 | −$2,975.00 | −$429.25 | 85.57% | $1.1M | $334,000.00 |
| Q4 2023 | Mar 25, 2024 | −$2,975.00 | $3,859.00 | 229.71% | $1.3M | $356,000.00 |
| Q3 2023 | Nov 14, 2023 | −$2,975.00 | −$629.00 | 78.86% | $780,000.00 | $282,000.00 |
| Q2 2023 | Aug 14, 2023 | −$3,400.00 | −$2,975.00 | 12.50% | $630,000.00 | $161,000.00 |
| Q1 2023 | May 15, 2023 | −$4,675.00 | −$4,675.00 | 0.00% | $520,000.00 | $376,000.00 |
| Q4 2022 | Mar 31, 2023 | −$13,175.00 | −$9,775.00 | 25.81% | $640,000.00 | $400,000.00 |
| Q3 2022 | Nov 14, 2022 | −$13,600.00 | −$11,475.00 | 15.63% | $660,000.00 | $477,000.00 |
| Q2 2022 | Aug 15, 2022 | −$10,200.00 | −$13,600.00 | -33.33% | $460,000.00 | $528,000.00 |
| Q1 2022 | May 16, 2022 | $0.00 | −$9,775.00 | 0.00% | — | $430,000.00 |

## Frequently Asked Questions

### When did Valion Bio (VBIO) last report earnings?

Valion Bio last reported on Nov 14, 2024, covering fiscal Q3 2024.

### Did VBIO beat earnings estimates?

Yes. Valion Bio reported EPS of −$97.75 for Q3 2024 against a −$2,550.00 estimate — a 96.17% beat.

### How much revenue did VBIO report last quarter?

Valion Bio reported $126,000.00 in revenue for Q3 2024, against a consensus estimate of $1.3M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).